COVID-19 rapid test FRCGFL 020

fluproteinSARS-COV-2

The FREND™ COVID-19 Ag + Flu A&B is a fluorescence immunoassay (FIA) for use with the FREND™ System. It is designed for the qualitative and simultaneous detection of the nucleocapsid protein of SARS-CoV-2 and Influenza A&B virus. It measures directly from nasopharyngeal swab specimens. KEY FEATURES & BENEFITS - 2 steps | Easy to use - Microfluidic Qualitative Immunoassay - LIS connectivity (data management) - COVID-19 Ag | 95.56 % & 99.66% Percent Agreement - Influenza A | 100.00 % & 99.67 % Percent Agreement - Influenza B | 97.50 % & 98.66 % Percent Agreement Microfluidic Qualitative Immunoassay FREND™ COVID-19 Ag + Flu A&B The FREND™ COVID-19 Ag + Flu A&B is a fluorescence immunoassay (FIA) for use with the FREND™ System. It is designed for the qualitative and simultaneous detection of the nucleocapsid protein of SARS-CoV-2 and Influenza A&B virus. It measures directly from nasopharyngeal swab specimens. With just simple steps of operation, the FREND™ system​​ supports quick decision-making. Performance evaluation Clinical agreement study [COVID-19 Ag] The total of 338 clinical samples (45 positive and 293 negative) confirmed with RT-PCR were tested. It shows 95.56% PPA (Positive Percent Agreement) and 99.66% NPA (Negative Percent Agreement) shown as below. [Influenza A] The total of 338 clinical samples (38 positive and 300 negative) confirmed with RT-PCR were tested. It shows 100% PPA (Positive Percent Agreement) and 99.67% NPA (Negative Percent Agreement) shown as below. [Influenza B] The total of 338 clinical samples (40 positive and 298 negative) confirmed with RT-PCR were tested.